文献速递细菌感染、耐药与抗菌药物

血清白蛋白水平与碳青霉烯类型对产ESBL大肠埃希菌和肺炎克雷伯菌菌血症30天死亡率无显著交互作用:一项多中心IPTW队列研究

Absence of Significant Interaction Between Serum Albumin Level and Carbapenem Type on 30-Day Mortality in ESBL-positive E. coli and K. pneumoniae Bacteremia: A Multicenter Cohort Study with Inverse Probability of Treatment Weighting Analysis.
PubMed 文献 · Clin Infect Dis · 2026-07-16

该多中心回顾性队列研究纳入573例产ESBL大肠埃希菌或肺炎克雷伯菌菌血症成人患者,采用IPTW平衡基线后分析血清白蛋白水平与碳青霉烯类型(组1 vs 组2)的交互作用。结果显示30天死亡率(P=0.92)和14天死亡率(P=0.36)均无显著交互作用,提示厄他培南疗效与组2碳青霉烯类相当,不受白蛋白水平影响。

要点

  • 血清白蛋白水平与碳青霉烯类型对30天和14天死亡率均无显著交互作用。
  • 在观察到的白蛋白范围内,厄他培南疗效与组2碳青霉烯类相当。
  • IDSA指南基于低白蛋白限制厄他培南的证据有限,本研究未支持该限制。

核心结论

  • 在观察到的血清白蛋白范围内,厄他培南治疗产ESBL肠杆菌目细菌菌血症的疗效与组2碳青霉烯类相当。

研究设计与样本

  • 多中心回顾性队列研究,纳入2013-2020年三所医院573例接受组1或组2碳青霉烯类单药治疗的产ESBL大肠埃希菌或肺炎克雷伯菌菌血症成人患者,采用IPTW平衡基线特征。

主要发现

  • IPTW伪人群包含565.1例加权患者(组1碳青霉烯374.9例,组2碳青霉烯190.2例),协变量平衡良好(所有标准化均数差<0.1)。
  • 总体30天死亡率为7.9%(44.9例加权死亡),14天死亡率为5.1%(29例加权死亡)。
  • 血清白蛋白水平与碳青霉烯类型对30天死亡率无显著交互作用(P=0.92),对14天死亡率亦无显著交互作用(P=0.36)。

关键数值与推荐

  • IDSA指南推荐对低白蛋白血症的产ESBL肠杆菌目细菌感染患者优先选用组2碳青霉烯类而非厄他培南(组1碳青霉烯),但支持该限制的临床证据有限。

临床怎么用

  • 对于产ESBL大肠埃希菌或肺炎克雷伯菌菌血症患者,厄他培南可作为组2碳青霉烯类的替代选择,无需仅因血清白蛋白水平而限制使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Infectious Diseases Society of America guidelines recommend group 2 carbapenems over ertapenem (group 1 carbapenem) for treating extended-spectrum β-lactamase (ESBL)-producing Enterobacterales infections in patients with hypoalbuminemia, but clinical evidence supporting this restriction of ertapenem is limited. We assessed whether the effect of serum albumin level on treatment outcome differed by carbapenem group in ESBL-producing bacteremia. METHODS: We conducted a multicenter retrospective cohort study at three hospitals, enrolling adults treated exclusively with either group 1 or group 2 carbapenems due to ESBL-positive E. coli or K. pneumoniae bacteremia (2013-2020). Baseline characteristics were balanced by inverse probability of treatment weighting (IPTW). Thirty-day mortality was analyzed using a multivariable weighted Cox proportional hazards model including an interaction term between serum albumin level and carbapenem group, and 14-day mortality was analyzed with the same interaction term in a multivariable weighted logistic regression model. RESULTS: From the 573 eligible patients, an IPTW pseudo-population of 565.1 weighted patients with good covariate balance (all standard mean differences <0.1) was analyzed (group 1 carbapenem, 374.9; group 2 carbapenem, 190.2) Overall 30-day and 14-day mortalities were 7.9% (44.9 weighted deaths) and 5.1% (29 weighted deaths), respectively. There was no significant interaction between serum albumin level and carbapenem group for either 30-day mortality (P = 0.92) or 14-day mortality (P = 0.36). CONCLUSION: The therapeutic efficacy of ertapenem appears to be comparable to that of group 2 carbapenems for the treatment of ESBL-producing Enterobacterales bacteremia across the observed range of serum albumin levels.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Jung EJ, Park JJ, Oh HS, et al. Absence of Significant Interaction Between Serum Albumin Level and Carbapenem Type on 30-Day Mortality in ESBL-positive E. coli and K. pneumoniae Bacteremia: A Multicenter Cohort Study with Inverse Probability of Treatment Weighting Analysis. Clin Infect Dis. 2026. PMID: 42461295. doi:10.1093/cid/ciag444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。